| Influence of antipsychotics on mortality in schizophrenia: systematic review. | |
| | |
MedLine Citation:
|
PMID: 19524406 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Antipsychotic medication is the cornerstone of schizophrenia treatment. The impact of long-term exposure to antipsychotics on life-expectancy has recently received some attention, partly because awareness is increasing of the differential mortality of people with schizophrenia and the general population. METHODS: A systematic review of studies assessing the association between antipsychotic exposure and mortality in persons with schizophrenia was undertaken. RESULTS: In total, 12 studies met the inclusion criteria. Three out of five studies examining antipsychotic dosage and higher mortality showed a significant association for one or more antipsychotics. Two out of four found negative effects of antipsychotic polypharmacy on life-expectancy. Some studies found a lower cardiovascular mortality risk with higher treatment intensity or when comparing current versus past or non-use of antipsychotics. Others established a stable correlation between antipsychotic exposure and an increase in cardiovascular mortality. Evidence for differential effects on mortality in favor of second generation (SGA) compared to first generation antipsychotics was inconsistent. No study of SGA drugs had a sufficient follow-up time. A major confounding factor may be a higher risk factor load for somatic disorders in the most severely mentally ill. CONCLUSION: There is some evidence that long-term exposure to antipsychotics increases mortality in schizophrenia. More rigorously designed, prospective studies are urgently needed. |
| | |
Authors:
|
Stefan Weinmann; John Read; Volkmar Aderhold |
Related Documents
:
|
16204326 - Rapid dose titration of quetiapine for the treatment of acute schizophrenia and acute m... 9589516 - Differences in the eeg profiles of early and late responders to antipsychotic treatment... 9193196 - Quetiapine in patients with schizophrenia. a high- and low-dose double-blind comparison... 17177576 - Aripiprazole in the treatment of schizophrenia: a consensus report produced by schizoph... 4044156 - Depressive disorders in the developing world. 19923806 - Vestibular function and vertigo control after intratympanic gentamicin for ménière's ... |
Publication Detail:
|
Type: Journal Article; Review Date: 2009-06-12 |
Journal Detail:
|
Title: Schizophrenia research Volume: 113 ISSN: 1573-2509 ISO Abbreviation: Schizophr. Res. Publication Date: 2009 Aug |
Date Detail:
|
Created Date: 2009-07-14 Completed Date: 2009-10-12 Revised Date: 2010-09-02 |
Medline Journal Info:
|
Nlm Unique ID: 8804207 Medline TA: Schizophr Res Country: Netherlands |
Other Details:
|
Languages: eng Pagination: 1-11 Citation Subset: IM |
Affiliation:
|
Institute for Social Medicine, Epidemiology and Health Economics, Charité University Medicine Berlin, Luisenstrasse 57, D-10117 Berlin, Germany. Stefan.Weinmann@charite.de |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antipsychotic Agents
/
adverse effects*,
classification,
therapeutic use* Databases, Factual / statistics & numerical data Humans Schizophrenia / drug therapy*, epidemiology, mortality* |
| Chemical | |
Reg. No./Substance:
|
0/Antipsychotic Agents |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Hypertriglyceridemic acute pancreatitis during pregnancy: prevention with diet therapy and omega-3 f...
Next Document: Sensory-gating deficit of the N100 mid-latency auditory evoked potential in medicated schizophrenia ...